Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038407 | 0.82 | MEN1 (0.41) | MAPTALDH1A1GAAPIN1 | |
| SCHEMBL2646047 | 0.79 | MAPT (0.39) | MAPTLMNAHTTALDH1A1GAA | |
| SCHEMBL564681 | 0.78 | MAPT (0.43) | MAPTLMNAHTTALDH1A1KDM4E | |
| SCHEMBL564672 | 0.76 | ALDH1A1 (0.36) | MAPTLMNAHTTALDH1A1PIN1 | |
| SCHEMBL2646046 | 0.76 | NR1H2 (0.38) | MAPTLMNAHTTALDH1A1GAA | |
| SCHEMBL563690 | 0.75 | HSPB1 (0.49) | MAPTLMNAHTTALDH1A1HSPB1 | |
| SCHEMBL1677224 | 0.74 | GPR119 (0.33) | — | |
| SCHEMBL2645356 | 0.74 | MAPT (0.44) | MAPTLMNAHTTALDH1A1GAA | |
| SCHEMBL3552351 | 0.73 | MAPT (0.40) | MAPTLMNAHTTALDH1A1HSPB1 | |
| SCHEMBL1039005 | 0.72 | CYP19A1 (0.43) | MAPTPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | MAPT 3676/4885LMNA 3434/4885HTT 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.